Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT06848829
Recruiting Not applicable

Difference of Tear Ferning Between Women with and Without Menopausal.

NCT06848829 · tracked via the Priya Life Science Taiwan tracker
Sponsor
Chung Shan Medical University
Phase
Not applicable
Started
2024-10-01
Last updated
2025-02-27

Condition(s) studied

Dry Eye Syndromes

Investigational drug(s) / intervention(s)

Pre-manepausal women

Pre-manepausal women: Compare tear ferning structure between pre-menopause and post-menopause women.

Study summary

Application of tear ferning test for clinical dry eye diagnosis and menopause

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Aged between 20 and 65 years Exclusion Criteria: * No evident ocular diseases such as cornea, cataracts, vitreous degeneration, glaucoma, and retinopathy. * Belong to vulnerable groups(pregnancy woman, prisoner, ethical minorities, economic or educationally disadvantaged subjects, disabled individuals such as those at terminal stage of tumorigenesis, blindness, terminal ill individuals)

Primary outcome measure(s)

  • Schirmer's test — 5 minutes
    To assess tear secretion volume
  • Tear film breakup time — 20 seconds
    To assess tear quality
  • Ocular surface status — 3 minutes
    To assess ocular surface health status with lissamine green stain, health or corneal abrasion.
  • Tear ferning — 30 minutes
    crystal structure formed from tear drops on a slide be scored.
  • Menopause related hormone Enzyme-linked immunosorbent assay (ELISA) — 3 hours
    To assess FSH/LH/E2/Progesterone/Mc5AC/Lactoferrin concentration between pre- and post-manopause women.

Trial sites (1)

FacilityCityRegionStatus
Jen-Ai Hospital Taichung Taiwan Recruiting

More Chung Shan Medical University trials in Taiwan

The Efficiency of a New Sperm-Wash Device for Intrauterine Insemination in Couples With Infertility Recruiting
The Effect of LDL557 on Improving Degenerative Arthritis in the Elderly Enrolling by invitation
Specimen and Clinical Data Collection Plan for LDCT Screening Participants Recruiting
Effects of a Multimodal Exercise Program on Physical Performance and Muscle Function in Middle-aged Patients With T2DM Active, not recruiting
Preadmission GLP-1 Receptor Agonist Plus SGLT2 Inhibitor Use and Early Outcomes After Pneumonia Hospitalization in Adults With Type 2 Diabetes Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06848829 on ClinicalTrials.gov ↗ ← All trials in Taiwan